Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry

被引:13
作者
Guetens, G
Prenen, H
DeBoeck, G
Van Dongen, W
Esmans, E
Lemière, F
van Oosterom, AT
Schöffski, P
de Bruijn, EA
机构
[1] Katholieke Univ Leuven Hosp, Dept Clin Oncol, Expt Oncol Lab, B-3000 Louvain, Belgium
[2] Univ Instelling Antwerp, Dept Chem, B-2610 Antwerp, Belgium
[3] Univ Antwerp, Dept Chem, Nucleoside Res & Mass Spectrometry Unit, B-2020 Antwerp, Belgium
[4] Univ Antwerp, Ctr Proteom & Mass Spectrometry, B-2020 Antwerp, Belgium
关键词
Iressa; on-column focusing; capillary liquid chromatography; tandem mass spectrometry; ZD-1839; plasma;
D O I
10.1016/j.chroma.2005.04.043
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The development of an on-column focusing gradient capillary LC method coupled to tandem mass spectrometry (quadrupole-linear ion trap) for the quantitative determination of the anticancer agent ZD 1839 (Gefitinib, tressa) in blood plasma is described. Plasma samples (0.2 ml) were extracted with methyl tert-butyl ether. The analytes of interest, ZD1839 and the internal standard [H-2(8)]ZD1839 (ZD1839-d8) were eluted on a 50 mm x 1 mm, 5 mu m particle size, capillary ODS Hypersil column using an aqueous ammonium acetate gradient at 40 mu l/min. Mass spectrometric detection was performed by a Q-Trap tandem mass spectrometer with electrospray positive ionisation, and monitored in the multiple reaction monitoring transitions 447 > 128 and 455 > 136, respectively. The limit of quantification of ZD 18395 was 0.1 ng/ml. The method proved to be robust, allowing quantification of ZD 1839 with sufficient precision, accuracy and sensitivity. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:2 / 5
页数:4
相关论文
共 16 条
  • [1] BASELGA J, 2000, P AN M AM SOC CLIN, V19, P686
  • [2] Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
  • [3] FERRY D, 2000, P AN M AM SOC CLIN, V19, P3
  • [4] Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry
    Guetens, G
    De Boeck, G
    Highley, M
    Dumez, H
    Van Oosterom, AT
    de Bruijn, EA
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2003, 1020 (01) : 27 - 34
  • [5] Antisense epidermal growth factor receptor delivered by adenoviral vector blocks tumor growth in human gastric cancer
    Hirao, T
    Sawada, H
    Koyama, F
    Watanabe, A
    Yamada, Y
    Sakaguchi, T
    Tatsumi, M
    Fujimoto, H
    Emoto, K
    Narikiyo, M
    Oridate, N
    Nakano, H
    [J]. CANCER GENE THERAPY, 1999, 6 (05) : 423 - 427
  • [6] A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials
    Jones, HK
    Stafford, LE
    Swaisland, HC
    Payne, R
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (1-2) : 221 - 228
  • [7] Kelly HC, 1998, ANN ONCOL, V9, P109
  • [8] Lavelle F, 1997, Expert Opin Investig Drugs, V6, P771, DOI 10.1517/13543784.6.6.771
  • [9] Moyer JD, 1997, CANCER RES, V57, P4838
  • [10] The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
    Prewett, M
    Rockwell, P
    Rockwell, RF
    Giorgio, NA
    Mendelsohn, J
    Scher, HI
    Goldstein, NI
    [J]. JOURNAL OF IMMUNOTHERAPY, 1996, 19 (06): : 419 - 427